Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18594693 | MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINASE LIKE 7 (PTK7) AND IMMUNE CELLS EXPRESSING SUCH | March 2024 | January 2026 | Abandon | 22 | 2 | 1 | No | No |
| 18497798 | DETERMINISTIC MECHANOPORATION FOR CELL ENGINEERING | October 2023 | July 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18463907 | USE OF CD33CAR MODIFIED HIGH AFFINITY NK CELLS (T-HANK) TO REDUCE MYELOID-DERIVED SUPPRESSOR CELLS SUPPRESSOR ACTIVITY (OR REDUCE NEGATIVE IMPACT ON NK CELL ACTIVITY) | September 2023 | October 2024 | Allow | 13 | 1 | 1 | No | No |
| 18203222 | NANOHELIX-SUBSTRATE COMPLEX FOR CONTROLLING MACROPHAGE BEHAVIOR, PREPARATION METHOD THEREOF, AND METHOD OF CONTROLLING ADHESION AND POLARIZATION OF MACROPHAGE BY USING THE SAME | May 2023 | August 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18125879 | DEVICES AND SYSTEMS FOR MIMICKING HEART FUNCTION | March 2023 | December 2025 | Allow | 33 | 0 | 0 | No | No |
| 18003282 | HYPERACTIVE TRANSPOSONS AND TRANSPOSASES | December 2022 | February 2026 | Allow | 38 | 0 | 1 | No | No |
| 18059540 | NOVEL HYDROGEL FOR 3D TISSUE ENGINEERING | November 2022 | December 2024 | Allow | 25 | 2 | 1 | No | No |
| 18000008 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17997982 | MASK PEPTIDES AND MASKED ANTI-PTK7 ANTIBODIES COMPRISING SUCH | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17910444 | ATOMIZED INHALATION FORMULATION CONTAINING HUMAN CELL-DERIVED EXTRACELLULAR VESICLES, PREPARATION METHOD AND USE THEREOF | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17817772 | PHOTO-CURABLE BIOINK TO FABRICATE ULTRA-STRONG, ELECTROCONDUCTIVE, AND BIOCOMPATIBLE HYDROGEL FOR REGENERATIVE MEDICINE | August 2022 | April 2024 | Allow | 20 | 1 | 1 | No | No |
| 17842344 | METHODS FOR PRODUCING NEURAL CELLS | June 2022 | November 2025 | Allow | 41 | 5 | 0 | No | No |
| 17692321 | METHODS OF VACCINATION AND USE OF CD47 BLOCKADE | March 2022 | August 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17686811 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS USING ANTI-CANCER COMPOSITION WITH MESENCHYMAL STEM CELLS CONDITIONED MEDIUM | March 2022 | April 2024 | Allow | 25 | 2 | 0 | No | No |
| 17680024 | ROR1 TARGETING CHIMERIC ANTIGEN RECEPTOR | February 2022 | July 2024 | Allow | 29 | 1 | 1 | No | No |
| 17579595 | USE OF HUMAN DECIDUAL MESENCHYMAL STEM CELL CULTURING SUPERNATANTS | January 2022 | December 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17575934 | PROCESS FOR ISOLATING NUCLEATED CELLS AND NUCLEATED CELL POPULATIONS AND USES THEREOF | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17626509 | METHOD FOR GENERATING CARDIAC TISSUE MIMETICS | January 2022 | September 2025 | Allow | 44 | 1 | 1 | No | No |
| 17570021 | CULTURE CONTAINER, METHOD FOR CULTURING LYMPHOCYTES, CULTURE-CONTAINER PRODUCTION METHOD, AND SOLID-PHASING APPARATUS | January 2022 | March 2026 | Abandon | 50 | 1 | 0 | No | No |
| 17292161 | METHOD FOR PRODUCING A BLOOD PRODUCT | November 2021 | February 2026 | Abandon | 57 | 2 | 1 | No | No |
| 17495768 | DETECTION AND TREATMENT OF DAUGHTER NUMBER VARIATIONS IN CANCER CELLS | October 2021 | February 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17487342 | ISL1 and LHX3 VECTOR | September 2021 | August 2025 | Abandon | 46 | 3 | 1 | No | Yes |
| 17598593 | Method of Generating Hemangioblasts | September 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17440543 | SICKLE CELL POTENCY ASSAY | September 2021 | September 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17439132 | METHOD OF CULTURING ANIMAL CELLS AND ENGINEERING TISSUE AND TISSUE-LIKE STRUCTURES | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17593184 | MINIMAL PROMOTER | September 2021 | May 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17436244 | ANTITUMOR CELL COMPRISING A CHARGE MODIFIED GLOBIN | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17436456 | THREE-DIMENSIONAL MUSCLE TISSUE AND PRODUCTION METHOD THEREFOR | September 2021 | November 2025 | Allow | 50 | 2 | 1 | No | No |
| 17432001 | CELL CULTURE MEDIUM AND METHOD FOR GENERATION OF EPITHELIAL ORGANOIDS FROM EPITHELIAL STEM CELLS | August 2021 | October 2024 | Allow | 38 | 1 | 1 | No | No |
| 17401513 | USE OF STEM CELL EXOSOMES FOR TREATING OVERACTIVE BLADDER | August 2021 | May 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17398653 | COMPOSITIONS FOR MAINTAINING THE VIABILITY OF LIVING AND STATIC BIOLOGICAL MATERIAL, METHODS OF MAKING AND THE USES THEREOF | August 2021 | December 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17429280 | MODIFIED MITOCHONDRION AND METHODS OF USE THEREOF | August 2021 | July 2025 | Allow | 47 | 1 | 1 | No | No |
| 17429274 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17391314 | IGE ANTIBODIES CROSS-REACTIVE TO ALLERGENS AND TUMOR ANTIGENS | August 2021 | May 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17427737 | STEM CELL GENERATOR AND CONSTRUCTION METHOD THEREFOR | August 2021 | October 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17380474 | STORAGE MEDIA FOR PRESERVATION OF CORNEAL TISSUE | July 2021 | April 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17305472 | PORTABLE OXYGEN SOURCE WITH PERFUSION SYSTEM | July 2021 | April 2024 | Allow | 33 | 2 | 1 | No | No |
| 17368883 | NANOHELIX-SUBSTRATE COMPLEX FOR CONTROLLING MACROPHAGE BEHAVIOR, PREPARATION METHOD THEREOF, AND METHOD OF CONTROLLING ADHESION AND POLARIZATION OF MACROPHAGE BY USING THE SAME | July 2021 | July 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17418474 | FREEZING OF BIOLOGICAL MATERIAL | June 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17356920 | COMPOSITIONS AND METHODS UTILIZING GENETICALLY-MODIFIED ANIMALS AND CELLS | June 2021 | September 2024 | Abandon | 39 | 3 | 1 | No | No |
| 17251537 | METHOD FOR CULTURING COLORECTAL CANCER SOLID TUMOR PRIMARY CELLS AND COLORECTAL CANCER ASCITES PRIMARY TUMOR CELLS AND SUPPORTING REAGENTS | June 2021 | April 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17299624 | UNDIFFERENTIATED STATE-MAINTAINING CULTURE MEDIUM FOR PLURIPOTENT STEM CELLS | June 2021 | June 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17320965 | SIMULTANEOUS DELIVERY OF CANCER TREATMENT PROGRAMS TO TUMOR AND IMMUNE CELLS | May 2021 | May 2025 | Abandon | 48 | 3 | 1 | No | No |
| 17292210 | BIOMARKER FOR PREDICTING ABILITY OF MESENCHYMAL STEM CELLS TO PROLIFERATE AND MIGRATE | May 2021 | April 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17313121 | MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINASE LIKE 7 (PTK7) AND IMMUNE CELLS EXPRESSING SUCH | May 2021 | November 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17243566 | METHODS FOR CULTURING CELLS | April 2021 | March 2025 | Allow | 46 | 4 | 1 | Yes | No |
| 17240902 | SARS-COV2 VACCINE VECTOR METHODS AND COMPOSITIONS | April 2021 | February 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17236352 | BIOPRINTED, 3D SCAFFOLDS FOR CELLULAR TEST BEDS AND METHODS OF USE THEREOF | April 2021 | November 2024 | Allow | 43 | 4 | 1 | Yes | No |
| 17286865 | METHODS FOR TISSUE GENERATION | April 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17231986 | DOC2B AS A BIOMARKER FOR TYPE 1 AND TYPE 2 DIABETES | April 2021 | December 2025 | Abandon | 56 | 2 | 1 | Yes | No |
| 17285338 | CHIMERIC MOLECULES | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17229790 | AAV-BASED GENE THERAPIES FOR TREATMENT OF AUTOIMMUNE DISEASES | April 2021 | January 2025 | Allow | 45 | 2 | 1 | No | No |
| 17284766 | IN VITRO CELL CULTURE MUCUS SYSTEMS | April 2021 | May 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17225708 | Deterministic Culturing of Single Cells | April 2021 | January 2025 | Allow | 46 | 2 | 1 | No | No |
| 17283516 | ORGANOID PRODUCED USING CARRIER FOR CELL CULTURE, AND METHOD FOR EVALUATING DRUG TOXICITY USING SAME | April 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17280225 | Generation of Post-Mitotic Migratory Cortical Interneurons | March 2021 | February 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17274543 | METHOD FOR PRODUCING INTESTINAL CELLS FROM PLURIPOTENT STEM CELLS | March 2021 | October 2024 | Abandon | 43 | 2 | 1 | Yes | No |
| 17271873 | A METHOD FOR DIRECT REPROGRAMMING OF URINE CELLS INTO NEURAL STEM CELLS USING SYNTHETIC MRNA | February 2021 | December 2024 | Allow | 46 | 2 | 1 | No | No |
| 17183689 | BCMA CAR-T CELLS WITH ENHANCED ACTIVITIES | February 2021 | March 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17270162 | METHOD FOR PRODUCING ENTERIC NEURAL PRECURSORS | February 2021 | October 2025 | Allow | 55 | 3 | 1 | No | No |
| 17250667 | COMBINED USE OF SQUIRREL POXVIRUS AND MYXOMA POXVIRUS, FOR TREATING CANCER | February 2021 | October 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17177501 | IN SITU ANALYSIS OF CHROMATIN INTERACTION | February 2021 | September 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17268656 | RECOMBINANT MYXOMA VIRUSES AND USES THEREOF | February 2021 | September 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17173806 | METHODS OF ACTIVATING REGULATORY T CELLS | February 2021 | April 2025 | Allow | 50 | 4 | 1 | No | No |
| 17171497 | STEM CELL DERIVED ISLET DIFFERENTIATION | February 2021 | September 2024 | Allow | 43 | 2 | 1 | No | No |
| 17267320 | ALGINATE HOLLOW MICROFIBER | February 2021 | September 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17265196 | METHODS AND COMPOSITIONS FOR CELL TRANSPLANTATION | February 2021 | January 2025 | Allow | 48 | 1 | 1 | No | No |
| 17150620 | RNA TICKERTAPE FOR RECORDING TRANSCRIPTIONAL HISTORIES OF CELLS | January 2021 | January 2026 | Abandon | 60 | 2 | 1 | No | No |
| 17259462 | AN INDUCER FOR INDUCING A MESENCHYMAL STEM CELL TO DIFFERENTIATE INTO AN ISLET CELL | January 2021 | April 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17257182 | METHOD FOR PRODUCING HUMAN INDUCED PLURIPOTENT STEM CELLS CONTAINING EXOGENOUS CHROMOSOME | December 2020 | October 2025 | Abandon | 57 | 4 | 0 | Yes | No |
| 17255618 | IN VIVO CONTROLLED COMBINATION THERAPY FOR TREATMENT OF CANCER | December 2020 | July 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17254055 | RECOMBINANT ADENO-ASSOCIATED VIRUS PRODUCTS AND METHODS FOR TREATING DYSTROGLYCANOPATHIES AND LAMININ-DEFICIENT MUSCULAR DYSTROPHIES | December 2020 | February 2026 | Allow | 60 | 1 | 1 | No | No |
| 17059874 | A MESENCHYMAL STEM CELL (MSC) GROWGH FACTOR AND EXTRACELLULAR VESICLE PREPARATION IN FROZEN OF POWDERED FORM AND METHODS OF USE | November 2020 | August 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 17102456 | ANTI-TUMOR COMPOSITION COMPRISING GM-CSF GENE, Flt3L-TRAIL FUSION GENE, shRNA INHIBITING TGF-ß EXPRESSION, AND shRNA INHIBITING HSP EXPRESSION | November 2020 | June 2025 | Abandon | 55 | 5 | 0 | Yes | No |
| 17056848 | Three-Dimensional Microporous Scaffold Device for Cell Culture | November 2020 | January 2026 | Allow | 60 | 3 | 1 | No | No |
| 17055328 | METHODS FOR TISSUE DECELLULARIZATION | November 2020 | October 2024 | Allow | 47 | 1 | 1 | No | No |
| 17055441 | COMPOSITION FOR PROMOTING STEM CELL DIFFERENTIATION, COMPRISING PROGENITOR CELL CULTURE SOLUTION AND MULTILAYER GRAPHENE FILM, AND USE THEREOF | November 2020 | July 2024 | Allow | 44 | 1 | 1 | No | No |
| 17054633 | METHOD OF DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MONOHORMONAL CELLS | November 2020 | May 2025 | Allow | 55 | 2 | 1 | No | No |
| 17054760 | GENE-DRIVE IN DNA VIRUSES | November 2020 | February 2025 | Allow | 51 | 1 | 1 | No | No |
| 17089284 | COMPOSITIONS AND METHODS FOR MODIFYING REGULATORY T CELLS | November 2020 | September 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17087614 | COMPOSITION FOR IMPROVING SKIN CONDITIONS COMPRISING A FRAGMENT OF HUMAN HEAT SHOCK PROTEIN 90A AS AN ACTIVE INGREDIENT | November 2020 | March 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17051744 | MESENCHYMAL STROMAL CELL EXOSOMES AND USES THEREOF | October 2020 | September 2025 | Allow | 58 | 2 | 1 | No | No |
| 17050362 | ENGINEERED AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS COMPRISING THE ENGINEERED CAPSIDS AND METHODS OF MAKING AND USING SAME | October 2020 | March 2026 | Allow | 60 | 2 | 1 | No | No |
| 17066642 | MESENCHYMAL-LIKE STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS, METHODS AND USES THEREOF | October 2020 | September 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17046756 | BICISTRONIC AAV VECTORS ENCODING HEXOSAMINIDASE ALPHA AND BETA-SUBUNITS AND USES THEREOF | October 2020 | July 2025 | Allow | 57 | 2 | 1 | No | No |
| 17065101 | Methods and Compositions for A HIV Based Delivery System | October 2020 | March 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17061360 | METHOD OF CULTURING CELLS, METHOD OF MANUFACTURING CELL SUPPORT COMPOSITE, CULTURED CELLS, AND CELL SUPPORT COMPOSITE | October 2020 | February 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17041788 | NOVEL DIFFERENTIATION TECHNIQUE TO GENERATE DOPAMINERGIC NEURONS FROM INDUCED PLURIPOTENT STEM CELLS | September 2020 | February 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 16982691 | METHODS OF USE OF ISLET CELLS | September 2020 | July 2024 | Allow | 46 | 1 | 1 | No | No |
| 16979981 | METHOD FOR PREPARING 3D BRAIN ORGANOIDS | September 2020 | October 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 17012486 | MOBILE-CRISPRI PLASMIDS AND RELATED METHODS | September 2020 | January 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 16976386 | METHODS AND COMPOSITIONS FOR TREATING ANGELMAN SYNDROME | August 2020 | September 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16968451 | CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | August 2020 | February 2025 | Allow | 55 | 2 | 1 | No | No |
| 16968511 | DOC2B AS A BIOMARKER FOR TYPE 1 DIABETES | August 2020 | November 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16962190 | METHOD FOR PRODUCING INSULIN-PRODUCING CELLS | July 2020 | February 2024 | Allow | 43 | 4 | 0 | Yes | No |
| 15733108 | Genome Edited iPSC-Derived Monocytes Expressing Trophic Factors | May 2020 | June 2025 | Abandon | 60 | 4 | 1 | No | No |
| 15930984 | STERILIZED TISSUE PRODUCTS AND RELATED METHODS | May 2020 | October 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16759705 | PLATFORM ONCOLYTIC VECTOR FOR SYSTEMIC DELIVERY | April 2020 | April 2024 | Allow | 48 | 3 | 1 | No | No |
| 16614297 | MULTIPLEX ASSAY | November 2019 | February 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16614205 | Targeted in Situ Therapeutic Delivery of Secreted Factors from Stem Cells for Treatment of Damaged Tissue | November 2019 | October 2025 | Allow | 60 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROGERS, ERIC JASON.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ROGERS, ERIC JASON works in Art Unit 1638 and has examined 82 patent applications in our dataset. With an allowance rate of 54.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner ROGERS, ERIC JASON's allowance rate of 54.9% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ROGERS, ERIC JASON receive 1.79 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ROGERS, ERIC JASON is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +32.5% benefit to allowance rate for applications examined by ROGERS, ERIC JASON. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.4% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.4% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 90.9% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.